BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li M, Li Y, Li J, Zhao P, Bai Y, Feng S, Liu X, Wang Y, Bian Q, Li J. Long-Term Effects of TCM Yangqing Kangxian Formula on Bleomycin-Induced Pulmonary Fibrosis in Rats via Regulating Nuclear Factor-κB Signaling. Evid Based Complement Alternat Med 2017;2017:2089027. [PMID: 29387126 DOI: 10.1155/2017/2089027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Zaafan MA, Haridy AR, Abdelhamid AM. Amitriptyline attenuates bleomycin-induced pulmonary fibrosis: modulation of the expression of NF-κβ, iNOS, and Nrf2. Naunyn Schmiedebergs Arch Pharmacol 2019;392:279-86. [PMID: 30474696 DOI: 10.1007/s00210-018-1586-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhou Z, Kandhare AD, Kandhare AA, Bodhankar SL. Hesperidin ameliorates bleomycin-induced experimental pulmonary fibrosis via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways. EXCLI J 2019;18:723-45. [PMID: 31611754 DOI: 10.17179/excli2019-1094] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
3 Liu B, Rong Y, Sun D, Li W, Chen H, Cao B, Wang T. Costunolide inhibits pulmonary fibrosis via regulating NF-kB and TGF-β1/Smad2/Nrf2-NOX4 signaling pathways. Biochem Biophys Res Commun 2019;510:329-33. [PMID: 30709583 DOI: 10.1016/j.bbrc.2019.01.104] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
4 Zhang Y, Lu P, Qin H, Zhang Y, Sun X, Song X, Liu J, Peng H, Liu Y, Nwafor EO, Li J, Liu Z. Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potential. Biomed Pharmacother 2021;133:111072. [PMID: 33378971 DOI: 10.1016/j.biopha.2020.111072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Maghsoudloo M, Azimzadeh Jamalkandi S, Najafi A, Masoudi-Nejad A. Identification of biomarkers in common chronic lung diseases by co-expression networks and drug-target interactions analysis. Mol Med 2020;26:9. [PMID: 31952466 DOI: 10.1186/s10020-019-0135-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
6 Ahmad A, Alkharfy KM, Jan BL, Ahad A, Ansari MA, Al-Jenoobi FI, Raish M. Thymoquinone treatment modulates the Nrf2/HO-1 signaling pathway and abrogates the inflammatory response in an animal model of lung fibrosis. Exp Lung Res 2020;46:53-63. [PMID: 32053036 DOI: 10.1080/01902148.2020.1726529] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
7 Ruwanpura SM, Thomas BJ, Bardin PG. Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease. Am J Respir Cell Mol Biol 2020;62:413-22. [PMID: 31967851 DOI: 10.1165/rcmb.2019-0328TR] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
8 Gan W, Huang Q, Xiao G, Luo Y, Wang J, Zhang C, Liang Y, Huang N, Liao T. Modified Maimendong decoction in the treatment of patients with idiopathic pulmonary fibrosis: Study protocol for a randomized controlled trial. Medicine (Baltimore) 2020;99:e23460. [PMID: 33285745 DOI: 10.1097/MD.0000000000023460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]